On Friday, Shares of Intel Corporation (NASDAQ:INTC), gained 1.16% to $28.81.
Andy Grove, the former CEO and Chairman of Intel, was honored late last week with the “Legendary Leader” Churchill Award from The Churchill Club, a long running Silicon Valley technology forum, according to ZD Net.
His award was accepted by Ben Horowitz, a VC who was impressed with Grove’s 1983 book “High Output Administration.”. There was also a video recording of Silicon Valley executives such as Mark Zuckerberg praising Grove.
A very frail looking Grove, 79 years old, took to the stage to thank everyone and spoke briefly.
Grove is credited with building a tough talking and hard working culture at Intel that propelled the company from a failing memory chip maker to a microprocessor manufacturer that dominates desktop and server markets. ZD Net Reports
Intel Corporation is engaged in the design and manufacture of digital technology platforms. The Company sells these platforms to original equipment manufacturers (OEMs), original design manufacturers (ODMs), and industrial and communications equipment manufacturers in the computing and communications industries.
Shares of Jabil Circuit, Inc. (NYSE:JBL), inclined 12.15% to $21.87, during its last trading session.
Jabil Circuit declared preliminary, unaudited financial results for its fourth quarter and full fiscal year, ended August 31, 2015. The company stated fourth quarter net revenue of $4.7 billion and fiscal year net revenue of $17.9 billion.
Fiscal 2015 Financial Highlights
- Total Company revenue of $17.9 billion, an improvement of 14% year-over-year.
- Diversified Manufacturing Services revenue: $7.1 billion, an improvement of 39% year-over-year.
- Electronics Manufacturing Services revenue: $10.8 billion, an improvement of 1% year-over-year.
- Generated $1.24 billion in cash flow from operations.
- Returned about $150 million to shareholders via dividend and share repurchases.
Jabil Circuit, Inc. provides electronic manufacturing services and solutions. The Company provides electronic design, production and product administration services to companies in the aerospace, automotive, computing, defense, digital home, energy, healthcare, industrial, instrumentation, lifestyles, mobility, mold, networking, packaging, peripherals, storage, telecommunications and wearable technology industries.
Shares of Denbury Resources Inc. (NYSE:DNR), declined -2.19% to $2.68, during its last trading session.
Denbury Resources has been assigned a consensus rating of “Hold” from the seventeen analysts that are covering the company, AnalystRatingsNetwork.com reports. Six equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $9.73.
Denbury Resources Inc. is an independent oil and natural gas company. The Company’s operations are focused in two operating areas: the Gulf Coast and Rocky Mountain regions. The Company’s properties with proved and producing reserves in the Gulf Coast region are situated in Mississippi, Texas, Louisiana and Alabama, and in the Rocky Mountain region are situated in Montana, North Dakota and Wyoming.
Finally, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), ended its last trade with -4.26% loss, and closed at $6.74.
Shares of Ariad Pharmaceuticals have been given a Buy-Sell rating of 2.33 by Zacks Research. This is based on 5 analyst reports taken into consideration. Brokerage research firms often use different terminology for their stock recommendations. In order to get a simplified consensus recommendation, Zacks uses a simplified 1 to 5 scale in order to obtain an Average Broker Rating. 1 represents a Strong Buy recommendation where 5 a Strong Sell. Stocks with a low rating means they are a Buy or Strong Buy based on analyst consensus opinion. A stock with a higher rating (3-5) yields an average recommendation of Hold, Sell or Strong Sell. Three months ago the stock had a 2.33 rating, which gives an idea of which direction sentiment is headed.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline comprises Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
